$OTLK

Outlook Therapeutics (OTLK) presented its commercial strategy for LYTENAVA, its newly FDA-approved eye drug, at the H.C. Wainwright conference. The company aims for a focused launch targeting practices dissatisfied with repackaged bevacizumab, with pricing under $500 per dose. Success hinges on payer access and a permanent billing code expected in 2027. OTLK's stock has fallen 58% year-to-date but rebounded 57% in six months, with a market cap of $161M. The company remains unprofitable, with neg

Outlook Therapeutics (OTLK) shares surged 140% after the FDA granted its appeal for Lytenava, an eye disease drug. The company plans to resubmit its BLA in 2026. Directors bought shares, and the company raised $5M in a direct offering. OTLK stock is up sharply this week but down 54% over the past year.

Outlook Therapeutics (OTLK) granted its CFO 500,000 stock options at $0.63 per share, expiring in 2036. The options vest over 4 years, with 25% vesting in 2027. The grant was made as an employment inducement under Nasdaq rules.

U.S. stock futures rose early Monday due to reports of a U.S.-Iran ceasefire, easing fears and leading to a crude oil price drop. Key companies like Nvidia (NVDA), Oracle (ORCL), and Outlook Therapeutics (OTLK) saw premarket movements. The week ahead includes major tech earnings and Fed decisions.

Outlook Therapeutics, Inc. (OTLK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer Transition On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, t

Outlook Therapeutics (OTLK) shares rose 21% after resubmitting its FDA application for Lytenava to treat nAMD, following a successful appeal. The FDA previously denied approval but now agrees no additional trials are needed. A decision is expected within 60 days. Lytenava, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab. The stock has fallen 50% over the past year.

Investing.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.

Outlook Therapeutics (NASDAQ:OTLK) CEO Robert Jahr bought 151,515 shares and 151,515 warrants on Aug. 14, 2026 at a combined public offering price of $0.99 per unit. Each warrant lets him buy one share at $1.10, exercisable immediately, expiring Aug. 14, 2031. The company also reported a narrower fiscal Q3 adjusted net loss of $10.9M ($0.09/share) and prepares to launch FDA-approved eye drug LYTENAVA.

Outlook Therapeutics (OTLK) disclosed an SEC Schedule 13D amendment from GMS Ventures and Ghiath M. Sukhtian. After the August 2026 offering, GMS Ventures beneficially owns 24,617,320 shares plus 18,013,822 warrants, about 16.4% of outstanding shares. GMS bought 2,525,252 shares and warrants for about $2.5 million at $0.99 per unit; warrants exercise at $1.10.

Outlook Therapeutics (OTLK) said insider-linked GMS Ventures, tied to director and 10% owner Ghiath M. Sukhtian, bought 2,525,252 shares at $0.99 each in an underwritten public offering on Aug. 12, 2026. GMS Ventures also received 2,525,252 warrants with a $1.10 exercise price, exercisable immediately and expiring Aug. 14, 2031.